SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)
BIOSEARCH MEDICAL PRODUCTS INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
90660
- --------------------------------------------------------------------------------
(CUSIP Number)
Steven N. Bronson
16 East 52nd Street
Suite 501
New York, New York 10022
(212) 872-1623
with a copy to:
Steven D. Dreyer, Esq.
Hall Dickler Kent Friedman & Wood LLP
909 Third Avenue
New York, New York 10022
(212) 339-5580
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
May 29, 1997
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
statement because of Rule 13d-1(b)(3) or (4), check the following box: |_|
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
CUSIP No. 90660 Page 2 of 4 Pages
- --------------------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Steven N. Bronson
- --------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group*
a. |_|
b. |_|
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Source of Funds*
PF
- --------------------------------------------------------------------------------
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) |_|
- --------------------------------------------------------------------------------
6 Citizenship or Place of Organization
USA
- --------------------------------------------------------------------------------
7 Sole Voting Power
Number of
Shares 301,494
Beneficially --------------------------------------------------------------
Owned By 8 Shared Voting Power
Each
Reporting 0
Person --------------------------------------------------------------
With 9 Sole Dispositive Power
301,494
--------------------------------------------------------------
10 Shared Dispositive Power
0
- --------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
301,494
- --------------------------------------------------------------------------------
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares* |_|
- --------------------------------------------------------------------------------
13 Percent of Class Represented By Amount in Row (11)
13.69%
- --------------------------------------------------------------------------------
14 Type of Reporting Person*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Page 3 of 4 Pages
Except as expressly amended below, the Schedule 13D, dated October 17,
1995, as amended, as filed on behalf of Steven N. Bronson with respect to the
shares of common stock ("Common Stock") of Biosearch Medical Products Inc., a
New Jersey corporation (the "Issuer"), remains in full force and effect.
Item 2. Identity and Background.
(a) This Statement on Schedule 13D is being filed on behalf of Steven N.
Bronson.
(b) The business address of Mr. Bronson is 16 East 52nd Street, Suite 501,
New York, New York 10022.
(c) Mr. Bronson is the President of Catalyst Financial Corp. ("Catalyst")
a broker-dealer registered under the Act.
(d) Mr. Bronson has not, during the last five years, been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) Mr. Bronson has not, during the last five years, been a party to a
civil proceeding of a judicial or administrative body of competent jurisdiction,
nor has Mr. Bronson been or is now subject to a judgment, decree, or final order
enjoining future violations of, or prohibiting or mandating activities subject
to federal or state securities laws or finding any violation with respect to
such laws.
(f) Mr. Bronson is a citizen of the United States of America.
Item 3. Source and Amount of Funds or Other Consideration.
On May 29, 1997 Mr. Bronson, utilizing his personal funds, acquired
45,000 shares of the Issuer's Common Stock for consideration of $.11 per share.
Item 5. Interest in Securities of the Issuer.
(a)(b)Mr. Bronson may be deemed to beneficially own an aggregate of
301,494 shares of Common Stock, representing approximately 13.69% of the total
shares of the Issuer's Common Stock outstanding. All 301,494 of such shares are
owned of record by Mr. Bronson and with respect to which Mr. Bronson may be
deemed to have sole voting and dispositive power.
<PAGE>
Page 4 of 4 Pages
The foregoing shares of Common Stock do not include any shares held of
record in the trading account of Catalyst and, with respect to such shares, Mr.
Bronson disclaims beneficial ownership.
(c) Not Applicable.
(d) No other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of such
securities of the Issuer.
(e) Not applicable.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information as set forth in this statement is true, complete
and correct.
Date: December 28, 1998 /s/ STEVEN N. BRONSON
------------------------
Steven N. Bronson
